好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Descriptive Nation-wide Survey of Laboratory Monitoring Practices of Multiple Sclerosis Clinicians in Canada
Multiple Sclerosis
P1 - Poster Session 1 (5:30 PM-6:30 PM)
15-097

To survey existing practices and perceptions of risk in laboratory monitoring throughout Canada and assess whether opportunities to improve patient care and safety exist.

Disease modifying therapies (DMTs) for multiple sclerosis (MS) effectively lower relapse rates and may prevent disease progression but can be associated with significant risks. The introduction of many new MS DMTs has increased the importance of laboratory monitoring for optimal patient care and safety.
A web-based survey assessing prescriber demographics, current infrastructure and concerns for lab monitoring was sent to the Canadian Network of MS Clinics (CNMSC) listserv, inviting MS clinicians across the country to participate.
Respondents included 32/65 CNMSC-affiliated neurologists (49%), 6 registered nurses (RN) 2 nurse practitioners (NP), and 2 non-neurologist physicians from 8/10 provinces. For some questions, analysis was limited to 34 DMT prescribing clinicians only. Despite broad implementation of electronic medical records (25/34, 74%), many prescribers (15/34,44%) still receive laboratory results in paper form. In terms of lab monitoring infrastructure, we noted regional variability in the employment of nursing to monitor patient compliance with required laboratory monitoring. There is also a gap in laboratory surveillance, as less than 5% of respondents reported regularly reviewing results on weekends. Providers’ length of practice and volume of MS patients were not associated with different perception of DMT laboratory monitoring risk.
This nation-wide survey showed variability in infrastructure used in laboratory monitoring and regional variation in nursing involvement.  Providers’ level of concern for laboratory monitoring for DMTs did not vary by years of experience or volume of MS patients followed, suggesting that improved systems, rather than education, could ameliorate perceptions of risk.
Authors/Disclosures
Aman Atwal
PRESENTER 		No disclosure on file
Alice J. Schabas, MD Dr. Schabas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Schabas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Schabas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Schabas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen.
Carolyn L. Taylor, MD No disclosure on file
No disclosure on file
Anthony Traboulsee, MD (University of British Columbia) Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Traboulsee has received research support from Roche. The institution of Dr. Traboulsee has received research support from Consortium of MS Centers. The institution of Dr. Traboulsee has received research support from MS Canada. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Workshop Chair with Consortium of MS Centers.
Krista Barclay No disclosure on file
Robert L. Carruthers, MD Dr. Carruthers has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Carruthers has received personal compensation in the range of $0-$499 for serving as a Consultant for Roche and Genentech. The institution of Dr. Carruthers has received research support from Roche and Genentech .